- Home
- NML vs PROK Comparison
NML vs PROK Comparison
Compare NML & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NML
- PROK
- Stock Information
- Founded
- NML 2012
- PROK 2015
- Country
- NML United States
- PROK United States
- Employees
- NML N/A
- PROK N/A
- Industry
- NML Finance/Investors Services
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NML Finance
- PROK Health Care
- Exchange
- NML Nasdaq
- PROK Nasdaq
- Market Cap
- NML 488.4M
- PROK 417.1M
- IPO Year
- NML N/A
- PROK N/A
- Fundamental
- Price
- NML $7.98
- PROK $2.97
- Analyst Decision
- NML
- PROK Strong Buy
- Analyst Count
- NML 0
- PROK 4
- Target Price
- NML N/A
- PROK $6.25
- AVG Volume (30 Days)
- NML 219.3K
- PROK 2.1M
- Earning Date
- NML 01-01-0001
- PROK 11-11-2025
- Dividend Yield
- NML 9.75%
- PROK N/A
- EPS Growth
- NML N/A
- PROK N/A
- EPS
- NML N/A
- PROK N/A
- Revenue
- NML N/A
- PROK $527,000.00
- Revenue This Year
- NML N/A
- PROK $427.89
- Revenue Next Year
- NML N/A
- PROK N/A
- P/E Ratio
- NML N/A
- PROK N/A
- Revenue Growth
- NML N/A
- PROK N/A
- 52 Week Low
- NML $6.09
- PROK $0.46
- 52 Week High
- NML $7.33
- PROK $7.13
- Technical
- Relative Strength Index (RSI)
- NML 26.47
- PROK 55.05
- Support Level
- NML $8.19
- PROK $2.80
- Resistance Level
- NML $8.68
- PROK $3.28
- Average True Range (ATR)
- NML 0.19
- PROK 0.27
- MACD
- NML -0.07
- PROK 0.01
- Stochastic Oscillator
- NML 10.00
- PROK 57.52
About NML Neuberger Berman Energy Infrastructure and Income Fund Inc.
Neuberger Berman Energy Infrastructure & Income Fund Inc is a closed-end investment management company based in the United States. Invest in Capital Markets, Chemicals, Oil, Gas & Consumable Fuels, Electric Utilities, Independent Power and Renewable Electricity Producers, Multi Utilities. Maximum is done in Oil, Gas & Consumable Fuels.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.